论文部分内容阅读
探索改善代谢综合征(metabolic syndrome,MS)多种代谢异常的有效药物对降低MS并发2型糖尿病和心血管病的危险性有重要的意义。研究表明过氧化物酶体增殖物激活受体δ(PPARδ)在激动剂的作用下可增加巨噬细胞胆固醇的逆向转运、升高高密度脂蛋白胆固醇(HDL-C),促进骨骼肌细胞脂肪酸的氧化、预防肥胖,增加胰岛素敏感性,抑制炎症反应、缩小动脉粥样硬化损伤面积而有潜在的抗动脉粥样硬化的作用,因此有望成为防治MS的新型药物作用靶点。
It is of great significance to explore effective drugs that can ameliorate many metabolic disorders of metabolic syndrome (MS) to reduce the risk of MS complicated with type 2 diabetes and cardiovascular diseases. Studies have shown that peroxisome proliferator-activated receptor δ (PPARδ) under the action of agonists can increase the reverse translocation of cholesterol in macrophages, increase high-density lipoprotein cholesterol (HDL-C), and promote the fatty acid Oxidation, prevention of obesity, increase insulin sensitivity, inhibit the inflammatory response, reduce the area of atherosclerotic lesions and potential anti-atherosclerotic role, it is expected to become a new drug targets for the prevention and treatment of MS.